The SARS‐CoV‐2 main protease (Mpro): Structure, function, and emerging therapies for COVID‐19

The SARS‐CoV‐2 main protease (Mpro): Structure, function, and emerging therapies for COVID‐19

Abstract The main proteases (Mpro), also termed 3‐chymotrypsin‐like proteases (3CLpro), are a class of highly conserved cysteine hydrolases in β‐coronaviruses. Increasing evidence has demonstrated that 3CLpros play an indispensable role in viral replication and have been recognized as key targets fo...

Full description

Bibliographic Details
Main Authors:	Qing Hu, Yuan Xiong, Guang‐Hao Zhu, Ya‐Ni Zhang, Yi‐Wen Zhang, Ping Huang, Guang‐Bo Ge
Format:	Article
Language:	English
Published:	Wiley 2022-09-01
Series:	MedComm
Subjects:	3‐chymotrypsin‐like protease (3CLpro) broad‐spectrum anti‐coronavirus agents SARS‐CoV‐2 β‐coronavirus 3CLpro inhibitor
Online Access:	https://doi.org/10.1002/mco2.151

Similar Items

<em>In silico</em> screening of potential compounds from begonia genus as 3CL protease (3Cl pro) SARS-CoV-2 inhibitors
by: Saipul Maulana, et al.
Published: (2023-03-01)

Crystallization of Feline Coronavirus Mpro With GC376 Reveals Mechanism of Inhibition
by: Jimmy Lu, et al.
Published: (2022-02-01)

Targeting SARS-CoV-2 Proteases for COVID-19 Antiviral Development
by: Zongyang Lv, et al.
Published: (2022-02-01)

Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 Mpro/3CLpro in Living Cells
by: Seyed Arad Moghadasi, et al.
Published: (2022-06-01)

Genetic Surveillance of SARS-CoV-2 Mpro Reveals High Sequence and Structural Conservation Prior to the Introduction of Protease Inhibitor Paxlovid
by: Jonathan T. Lee, et al.
Published: (2022-08-01)

Anthraquinone Derivatives as an Immune Booster and their Therapeutic Option Against COVID-19
by: Pukar Khanal, et al.
Published: (2020-08-01)

Natural Products-Based Drug Design against SARS-CoV-2 Mpro 3CLpro
by: Rai C. Silva, et al.
Published: (2021-10-01)

In-silico study MM/GBSA binding free energy and molecular dynamics simulation of some designed remdesivir derivatives as the inhibitory potential of SARS-CoV-2 main protease
by: Maryam Abbasi, et al.
Published: (2024-01-01)

High-Throughput Screening for Inhibitors of the SARS-CoV-2 Protease Using a FRET-Biosensor
by: Alistair S. Brown, et al.
Published: (2020-10-01)

A reporter cell line for the automated quantification of SARS-CoV-2 infection in living cells
by: Lowiese Desmarets, et al.
Published: (2022-09-01)

Myricetin Inhibits SARS-CoV-2 Viral Replication by Targeting Mpro and Ameliorates Pulmonary Inflammation
by: Ting Xiao, et al.
Published: (2021-06-01)

Structural and Biochemical Analysis of the Dual Inhibition of MG-132 against SARS-CoV-2 Main Protease (Mpro/3CLpro) and Human Cathepsin-L
by: Elisa Costanzi, et al.
Published: (2021-10-01)

Computational Studies of SARS-CoV-2 3CLpro: Insights from MD Simulations
by: Alessandro Grottesi, et al.
Published: (2020-07-01)

Identification of Anti-HIV/Migraine Drugs as Potential Inhibitors of SARS-Cov2 Main Protease Using in Silico Assessments
by: Hanifeh Shariatifar, et al.
Published: (2022-10-01)

TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease (3CLpro): Potential therapeutic intervention to combat COVID-19
by: Mohammad Azam Ansari, et al.
Published: (2020-11-01)

Study of Baicalin toward COVID-19 Treatment: In silico Target Analysis and in vitro Inhibitory Effects on SARS-CoV-2 Proteases
by: Chingju Lin, et al.
Published: (2021-11-01)

A novel class of broad-spectrum active-site-directed 3C-like protease inhibitors with nanomolar antiviral activity against highly immune-evasive SARS-CoV-2 Omicron subvariants
by: Jimena Pérez-Vargas, et al.
Published: (2023-12-01)

Discovery of 3CLpro inhibitor of SARS-CoV-2 main protease
by: Yi Kuang, et al.
Published: (2023-04-01)

In silico analysis of Phyllanthus amarus phytochemicals as potent drugs against SARS-CoV-2 main protease
by: T.P. Krishna Murthy, et al.
Published: (2021-01-01)

Binding kinetics of ten small-molecule drug candidates on SARS-CoV-2 3CLpro revealed by biomolecular simulations
by: Yifei Zhou, et al.
Published: (2023-12-01)

Identification of SARS-CoV-2 Main Protease Inhibitors Using Chemical Similarity Analysis Combined with Machine Learning
by: Karina Eurídice Juárez-Mercado, et al.
Published: (2024-02-01)

Insilico generation of novel ligands for the inhibition of SARS-CoV-2 main protease (3CLpro) using deep learning
by: Prejwal Prabhakaran, et al.
Published: (2023-06-01)

Repurposing of Drugs for SARS-CoV-2 Using Inverse Docking Fingerprints
by: Marko Jukič, et al.
Published: (2021-12-01)

SARS-CoV-2 proteases PLpro and 3CLpro cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species
by: Mehdi Moustaqil, et al.
Published: (2021-01-01)

In silico discovery of 3 novel quercetin derivatives against papain-like protease, spike protein, and 3C-like protease of SARS-CoV-2
by: Kunal Bhattacharya, et al.
Published: (2022-03-01)

A Computer-Aided Approach for the Discovery of D-Peptides as Inhibitors of SARS-CoV-2 Main Protease
by: Jorge E. Hernández González, et al.
Published: (2022-01-01)

Potent 3CLpro inhibitors effective against SARS-CoV-2 and MERS-CoV in animal models by therapeutic treatment
by: Pengfei Li, et al.
Published: (2024-02-01)

In silico screening of phenylethanoid glycosides, a class of pharmacologically active compounds as natural inhibitors of SARS-CoV-2 proteases
by: Caio Felipe de Araujo Ribas Cheohen, et al.
Published: (2023-01-01)

Ovatodiolide inhibits SARS-CoV-2 replication and ameliorates pulmonary fibrosis through suppression of the TGF-β/TβRs signaling pathway
by: Wei-Chung Chiou, et al.
Published: (2023-05-01)

Insights into the Dynamics and Binding of Two Polyprotein Substrate Cleavage Points in the Context of the SARS-CoV-2 Main and Papain-like Proteases
by: Zainab Kemi Sanusi, et al.
Published: (2022-11-01)

Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition
by: Aleix Gimeno, et al.
Published: (2020-05-01)

Polyphenols vs. Coronaviruses: How Far Has Research Moved Forward?
by: Simona Piccolella, et al.
Published: (2020-09-01)

Assessment of a Computational Approach to Predict Drug Resistance Mutations for HIV, HBV and SARS-CoV-2
by: Dharmeshkumar Patel, et al.
Published: (2022-08-01)

Synthesis, in silico and in vitro studies of novel quinazolinone derivatives as potential SARS-CoV-2 3CLpro inhibitors
by: Mubarak A. Alamri, et al.
Published: (2024-01-01)

Pharmacoinformatic study of inhibitory potentials of selected flavonoids against papain-like protease and 3-chymotrypsin-like protease of SARS-CoV-2
by: Habibu Tijjani, et al.
Published: (2022-09-01)

Potential Broad Spectrum Inhibitors of the Coronavirus 3CLpro: A Virtual Screening and Structure-Based Drug Design Study
by: Michael Berry, et al.
Published: (2015-12-01)

The Structure of the Porcine Deltacoronavirus Main Protease Reveals a Conserved Target for the Design of Antivirals
by: Fenghua Wang, et al.
Published: (2022-02-01)

Docking and Electronic Structure of Rutin, Myricetin, and Baicalein Targeting 3CLpro
by: Sergio A. de S. Farias, et al.
Published: (2023-10-01)

Chloropyridinyl Esters of Nonsteroidal Anti-Inflammatory Agents and Related Derivatives as Potent SARS-CoV-2 3CL Protease Inhibitors
by: Arun K. Ghosh, et al.
Published: (2021-09-01)

Recent advances in chemometric modelling of inhibitors against SARS-CoV-2
by: Qianqian Wang, et al.
Published: (2024-01-01)